# WT1 Vaccine Treatment of Patients in Remission From Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL)

> **NCT01266083** · PHASE2 · COMPLETED · sponsor: **Sellas Life Sciences Group** · enrollment: 22 (actual)

## Conditions studied

- Acute Myeloid Leukemia
- Acute Lymphoblastic Leukemia

## Interventions

- **BIOLOGICAL:** Galinpepimut-S
- **BIOLOGICAL:** GM-CSF
- **OTHER:** Montanide

## Key facts

- **NCT ID:** NCT01266083
- **Lead sponsor:** Sellas Life Sciences Group
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-01-14
- **Primary completion:** 2016-09-30
- **Final completion:** 2016-09-30
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2024-11-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01266083

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01266083, "WT1 Vaccine Treatment of Patients in Remission From Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01266083. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*